Legend Biotech (LEGN) Stock Forecast & Price Target

$39.85 +1.45 (+3.78%)

(As of 12:16 PM ET)

Legend Biotech - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 13 Analyst Ratings

Sell
0

Hold
0

Buy
13

Based on 13 Wall Street analysts who have issued ratings for Legend Biotech in the last 12 months, the stock has a consensus rating of "Buy." Out of the 13 analysts, 13 have given a buy rating for LEGN.

Consensus Price Target

$81.46
104.42% Upside

According to the 13 analysts' twelve-month price targets for Legend Biotech, the average price target is $81.46. The highest price target for LEGN is $94.00, while the lowest price target for LEGN is $60.00. The average price target represents a forecasted upside of 104.42% from the current price of $39.85.

LEGN Analyst Ratings Over Time

Type	Current Forecast 11/21/23 to 11/20/24	1 Month Ago 10/22/23 to 10/21/24	3 Months Ago 8/23/23 to 8/22/24	1 Year Ago 11/21/22 to 11/21/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	13 Buy rating(s)	14 Buy rating(s)	13 Buy rating(s)	11 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	1 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$81.46	$82.08	$81.78	$82.01
Forecasted Upside	104.42% Upside	88.90% Upside	42.52% Upside	43.25% Upside
Consensus Rating	Buy	Buy	Buy	Moderate Buy

[625,000% Gain] – Are You Ready for the Next Altcoin Boom? (Ad)

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

LEGN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

LEGN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Legend Biotech Stock vs. The Competition

Type	Legend Biotech	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.80	2.50
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	112.14% Upside	26,877.41% Upside	10.26% Upside
News Sentiment Rating	Neutral News See Recent LEGN News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/13/2024	HC Wainwright 2 of 5 stars		Reiterated Rating	Buy ➝ Buy	$73.00 ➝ $73.00	+81.68%
10/29/2024	Royal Bank of Canada 4 of 5 stars		Reiterated Rating	Outperform ➝ Outperform	$86.00 ➝ $86.00	+88.56%
10/8/2024	Redburn Atlantic 0 of 5 stars	Q. Ding Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$86.00	+73.46%
8/12/2024	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Sector Outperform ➝ Sector Outperform	$70.00 ➝ $76.00	+31.53%
7/15/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$71.00 ➝ $67.00	+23.25%
7/3/2024	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$90.00 ➝ $90.00	+101.16%
Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners (Ad) The "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners… Claim your FREE 2024 Gold Guide
6/17/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$90.00 ➝ $90.00	+113.57%
6/17/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Goonewardene Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$88.00	+107.30%
5/23/2024	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$60.00	+40.85%
4/3/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Overweight	$82.00	+45.31%
3/18/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$76.00 ➝ $81.00	+24.98%
3/13/2024	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$86.00	+32.04%
1/24/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$93.00 ➝ $94.00	+56.41%
11/6/2023	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$90.09	+36.56%
8/2/2023	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy
7/20/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight	$65.00 ➝ $85.00	+13.11%
6/12/2023	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$85.00 ➝ $90.00	+31.79%
5/25/2023	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Corwin Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Market Perform	$64.00	-3.09%
5/22/2023	Daiwa Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy
4/19/2023	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight	$65.00 ➝ $76.00	+21.60%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 12:35 PM ET.

LEGN Forecast - Frequently Asked Questions

: According to the research reports of 13 Wall Street equities research analysts, the average twelve-month stock price forecast for Legend Biotech is $81.46, with a high forecast of $94.00 and a low forecast of $60.00.
: 13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Legend Biotech in the last twelve months. There are currently 13 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" LEGN shares.
: According to analysts, Legend Biotech's stock has a predicted upside of 104.42% based on their 12-month stock forecasts.
: Legend Biotech has been rated by research analysts at HC Wainwright, Redburn Atlantic, and Royal Bank of Canada in the past 90 days.
: Analysts like Legend Biotech more than other "medical" companies. The consensus rating for Legend Biotech is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how LEGN compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Tesla Execs are Freaking Out (Ad)

It’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands on it. And Elon Musk has completely restructured Tesla to chase this opportunity. This is a once-in-a-lifetime opportunity that you don’t want to miss.

Click here to get the details.

This page (NASDAQ:LEGN) was last updated on 11/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

Get Started with MarketBeat

	Read Your Daily Newsletter
	Check Out My MarketBeat
	Watch Our Tutorial Videos
	Add a Stock to Your Watchlist
	Set Up an Instant Alert
	View a Company's Profile Page
	View Our Financial Calendars
	View Today's Analyst Ratings

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Legend Biotech (LEGN) Stock Forecast & Price Target